SBIR Phase I: Synthesis of Long RNA Oligonucleotides via Enzymatic Ligation

Information

  • NSF Award
  • 0109829
Owner
  • Award Id
    0109829
  • Award Effective Date
    7/1/2001 - 23 years ago
  • Award Expiration Date
    12/31/2001 - 23 years ago
  • Award Amount
    $ 100,000.00
  • Award Instrument
    Standard Grant

SBIR Phase I: Synthesis of Long RNA Oligonucleotides via Enzymatic Ligation

This Small Business Innovation Research (SBIR) Phase I project seeks to develop methods to prepare 60-200 base RNA/DNA oligonucleotides. Current methods for preparing long oligonucleotides suffer from limitations that hinder their application in biological science. Investigators have expressed an immediate need for longer material incorporating unnatural modifications and non-canonical substitutions. Access to these oligonucleotides is critical for continued discoveries in molecular biology and nucleic acid based therapeutics. Despite such demand, the most reliable synthetic method, 2-ACE chemistry, can provide quality oligonucleotides no longer than 50 bases. This SBIR Phase I project will use 2-ACE RNA to develop a novel biochemical technique using RNA ligase to enzymatically splice oligonucleotides together. RNA substrates will be coupled as part of a complex with a complementary splint. This project will evaluate different conformations of the ligation site, the tolerance of the enzyme for different substrate sequences, the optimal design and composition of the splint, and the ideal concentrations of substrates and cofactors. Once determined in an iterative process, the best conditions will be applied to more challenging research problems identified by collaborators. This research will directly address a critical deficit in the resources available to the national biotechnology research community.<br/><br/><br/>The commercial applications of this project are expected to be varied and immediate. As example, site-specifically modified RNAs of 50-200 bases in length should be in high demand by investigators who are developing RNA-targeted drugs or other RNA-dependent technologies beyond the reach of current synthetic means.

  • Program Officer
    Om P. Sahai
  • Min Amd Letter Date
    6/15/2001 - 23 years ago
  • Max Amd Letter Date
    6/15/2001 - 23 years ago
  • ARRA Amount

Institutions

  • Name
    DHARMACON INC
  • City
    LAFAYETTE
  • State
    CO
  • Country
    United States
  • Address
    2650 CRESCENT DR
  • Postal Code
    800266337
  • Phone Number
    3036049499

Investigators

  • First Name
    Stephen
  • Last Name
    Scaringe
  • Email Address
    scaringe@indra.com
  • Start Date
    6/15/2001 12:00:00 AM

FOA Information

  • Name
    Health
  • Code
    203000
  • Name
    Biomaterials-Short & Long Terms
  • Code
    510402